Aquestive Therapeutics (AQST) Accumulated Expenses (2018 - 2026)
Aquestive Therapeutics has reported Accumulated Expenses over the past 8 years, most recently at $5.0 million for Q4 2025.
- For Q4 2025, Accumulated Expenses fell 14.86% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, down 14.86%, while the annual FY2025 figure was $5.0 million, 14.86% down from the prior year.
- Accumulated Expenses for Q4 2025 was $5.0 million at Aquestive Therapeutics, down from $5.1 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $8.7 million in Q4 2021 and troughed at $3.3 million in Q1 2025.
- A 5-year average of $5.9 million and a median of $5.6 million in 2023 define the central range for Accumulated Expenses.
- Biggest five-year swings in Accumulated Expenses: surged 370.55% in 2021 and later plummeted 39.46% in 2023.
- Year by year, Accumulated Expenses stood at $8.7 million in 2021, then dropped by 8.8% to $8.0 million in 2022, then fell by 18.45% to $6.5 million in 2023, then fell by 9.08% to $5.9 million in 2024, then fell by 14.86% to $5.0 million in 2025.
- Business Quant data shows Accumulated Expenses for AQST at $5.0 million in Q4 2025, $5.1 million in Q3 2025, and $5.0 million in Q2 2025.